Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study
Dongdong Wang, Xiao Chen, Zhiping Li, Dongdong Wang, Xiao Chen, Zhiping Li
Abstract
Numerous studies have established population pharmacokinetics (PPK) models of sirolimus in various populations. However, a PPK model of sirolimus in Chinese patients with pediatric kaposiform hemangioendothelioma (PKHE) has yet to be established; therefore, this was the purpose of the present study. The present study was a retrospective analysis that utilized the trough concentration data obtained from traditional therapeutic drug monitoring-based dose adjustments. A total of 17 Chinese patients with PKHE from a real-world study were characterized by non-linear mixed-effects modeling. The impact of demographic features, biological characteristics and concomitant medications was assessed. The developed final model was evaluated via bootstrap and a prediction-corrected visual predictive check. A one-compartment model with first-order absorption and elimination was used for modeling of data for PKHE. The typical values of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) in the final model were 3.19 l/h and 165 liters, respectively. Age, alanine transaminase levels and sex were included as significant covariates for CL/F, while the duration of treatment with sirolimus was a significant covariate for V/F. In conclusion, the present study developed and validated the first sirolimus PPK model for Chinese patients with PKHE.
Keywords: kaposiform hemangioendothelioma; pediatric; population pharmacokinetics; real-world study; sirolimus.
Figures
References
- Reichel A, Hamm H, Wiegering V, Wiewrodt B, Neubauer H, Ernestus K, Winkler B. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: Successful treatment with sirolimus. J Dtsch Dermatol Ges. 2017;15:329–331. doi: 10.1111/ddg.12987.
- DeFatta RJ, Verret DJ, Adelson RT, Gomez A, Myers LL. Kaposiform hemangioendothelioma: Case report and literature review. Laryngoscope. 2005;115:1789–1792. doi: 10.1097/01.mlg.0000176539.94515.75.
- Yasui N, Koh K, Kato M, Park MJ, Tomizawa D, Oshima K, Uchisaka N, Gocho Y, Arakawa A, Seki M, et al. Kasabach-Merritt phenomenon: A report of 11 cases from a single institution. J Pediatr Hematol Oncol. 2013;35:554–558. doi: 10.1097/MPH.0b013e318281558e.
- Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CC., III Kaposiform hemangioendothelioma: Atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013;162:142–147. doi: 10.1016/j.jpeds.2012.06.044.
- Yadav D, Maheshwari A, Aneja S, Seth A, Chandra J. Neonatal Kasabach-Merritt phenomenon. Indian J Med Paediatr Oncol. 2011;32:238–241. doi: 10.4103/0971-5851.95150.
- Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer. 2010;55:1396–1398. doi: 10.1002/pbc.22766.
- Iacobas I, Simon ML, Amir T, Gribbin CE, McPartland TG, Kaufman MR, Calderwood S, Nosher JL. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms. Clin Imaging. 2015;39:529–532. doi: 10.1016/j.clinimag.2015.01.003.
- Jahnel J, Lackner H, Reiterer F, Urlesberger B, Urban C. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: From vincristine to sirolimus. Klin Padiatr. 2012;224:395–397. doi: 10.1055/s-0032-1323823.
- Kai L, Wang Z, Yao W, Dong K, Xiao X. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol. 2014;140:471–476. doi: 10.1007/s00432-013-1549-3.
- Adams DM, Trenor CC, III, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137:e20153257. doi: 10.1542/peds.2015-3257.
- Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 1997;37:405–415. doi: 10.1002/j.1552-4604.1997.tb04318.x.
- MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000;22(Suppl B):B101–B121. doi: 10.1016/S0149-2918(00)89027-X.
- Chevillard L, Sabo N, Tod M, Labat L, Chasport C, Chevaleyre C, Thibaut F, Barre J, Azuar J, Questel F, et al. Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients. Fundam Clin Pharmacol. 2018;32:239–248. doi: 10.1111/fcp.12330.
- Marsot A, Michel F, Chasseloup E, Paut O, Guilhaumou R, Blin O. Phenobarbital in intensive care unit pediatric population: Predictive performances of population pharmacokinetic model. Fundam Clin Pharmacol. 2017;31:558–566. doi: 10.1111/fcp.12291.
- Wang DD, Lu JM, Li Q, Li ZP. Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. J Clin Pharm Ther. 2018;43:476–483. doi: 10.1111/jcpt.12707.
- Vadcharavivad S, Praisuwan S, Techawathanawanna N, Treyaprasert W, Avihingsanon Y. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: Comparison with similar data from other populations. J Clin Pharm Ther. 2016;41:310–328. doi: 10.1111/jcpt.12396.
- Jiao Z, Shi XJ, Li ZD, Zhong MK. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. Br J Clin Pharmacol. 2009;68:47–60. doi: 10.1111/j.1365-2125.2009.03392.x.
- Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51–64. doi: 10.1016/S0169-2607(98)00067-4.
- Fasolo A, Sessa C. Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs. 2011;20:381–394. doi: 10.1517/13543784.2011.541154.
- Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet. 1992;22:447–467. doi: 10.2165/00003088-199222060-00004.
- Kauffman RE, Kearns GL. Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin Pharmacokinet. 1992;23:10–29. doi: 10.2165/00003088-199223010-00002.
- Emoto C, Fukuda T, Mizuno T, Schniedewind B, Christians U, Adams DM, Vinks AA. Characterizing the developmental trajectory of sirolimus clearance in neonates and infants. CPT Pharmacometrics Syst Pharmacol. 2016;5:411–417. doi: 10.1002/psp4.12096.
- Mizuno T, Fukuda T, Emoto C, Mobberley-Schuman PS, Hammill AM, Adams DM, Vinks AA. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer. 2017:64. doi: 10.1002/pbc.26470.
- Mizuno T, Emoto C, Fukuda T, Hammill AM, Adams DM, Vinks AA. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. Eur J Pharm Sci 109S. 2017:S124–S131. doi: 10.1016/j.ejps.2017.05.037.
- Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998;285:1104–1112.
- Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753–761.
- Yang JW, Liao SS, Zhu LQ, Zhao Y, Zhang Y, Sun XY, Rao W, Qu W, Li WZ, Sun LY. Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther. 2015;53:75–83. doi: 10.5414/CP202189.
- Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–332. doi: 10.1146/annurev.pharmtox.48.113006.094708.
- Wang DD, Chen X, Li ZP. Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. J Clin Pharm Ther. 2019 Mar 12; doi: 10.1111/jcpt.12828. doi: 10.1111/jcpt.12828 (Epub ahead of print)
- Wang D, Chen X, Xu H, Li Z. Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. Xenobiotica. 2019:1–8. doi: 10.1080/00498254.2018.1563732. (Epub ahead of print)
- Wang D, Chen X, Li Z. Cyclosporin population pharmacokinetics in pediatric refractory nephrotic syndrome based on real-world studies: Effects of body weight and spirolactone administration. Exp Ther Med. 2019;17:3015–3020.
- Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J. 2004;6:e28. doi: 10.1208/aapsj060428.
- Dansirikul C, Morris RG, Tett SE, Duffull SB. A Bayesian approach for population pharmacokinetic modelling of sirolimus. Br J Clin Pharmacol. 2006;62:420–434. doi: 10.1111/j.1365-2125.2005.02533.x.
- Tejani A, Alexander S, Ettenger R, Lerner G, Zimmerman J, Kohaut E, Briscoe DM. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant. 2004;8:151–160. doi: 10.1046/j.1399-3046.2003.00137.x.
- Emoto C, Fukuda T, Venkatasubramanian R, Vinks AA. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: Insights from predictions with a physiologically-based pharmacokinetic model. Br J Clin Pharmacol. 2015;80:1438–1446. doi: 10.1111/bcp.12743.
- Wang M, Duan BL, Yuan YJ, Su X, Zheng H, Wang FS, Sun H. Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients. Int J Clin Pharmacol Ther. 2016;54:433–441. doi: 10.5414/CP202499.
- Mizuno T, Fukuda T, Christians U, Perentesis JP, Fouladi M, Vinks AA. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: A report from the Children's Oncology Group. Br J Clin Pharmacol. 2017;83:1097–1107. doi: 10.1111/bcp.13181.
Source: PubMed